Aktis Oncology News and Activities

Presence

Aktis Oncology develops targeted cancer medicines using radiopharmaceutical technology. Its main products are drug candidates and research services for hospitals, cancer centers, and pharmaceutical partners.

Aktis Oncology products and services overview:

Cancer therapeutics
Radiopharmaceuticals
Drug discovery
Clinical development

Revenue: ~$0 million

Employees: 55

Headquarters: Boston, United States (USA)

Aktis Oncology is one of the...

Aktis Oncology is a company listed under the stock ticker AKTS (US).

Acquisition, funding and merger involving Aktis Oncology.

Aktis Oncology has just announced a $181 Million fundraising (posted on January 8 2026).
Aktis Oncology has just announced a $175 Million fundraising (posted on October 2 2024).

Executives

View the org chart displaying its 32 main executives

Most searched biographies at Aktis Oncology

Popular executive movements at Aktis Oncology

Oleg Nodelman, Director, will leave the company on May 20, 2026 (posted on April 17 2026).
Helen Kim, Director, will leave the company on May 20, 2026 (posted on April 17 2026).
Glenn Gormley has joined the company as Director (posted on April 17 2026).

Click here to view some more movements at Aktis Oncology

Create your alert
to follow the executive moves at Aktis Oncology.